Next step in the development of mesoprogestins: the preclinical profile of EC313

Medicine and Dentistry

• Androgen Receptor 16%
• Antigestagen 16%
• Assay 16%
• Chemotherapeutic Agent 16%
• Development 100%
• Differentiation 16%
• Drug 16%
• Drug Megadose 16%
• Endometriosis 33%
• Endometrium 16%
• Estradiol Receptor 16%
• Estrogen 16%
• Gestagen 33%
• Glucocorticoid 33%
• Glucocorticoid Receptor 16%
• Growth 33%
• Gynecologic Disease 16%
• Human 16%
• In Vitro 33%
• Lesion 16%
• Ligand 16%
• Low Drug Dose 33%
• Mifepristone 33%
• Mineralocorticoid Receptor 16%
• Pharmacodynamics 16%
• Pharmacological Target 16%
• Pig Study 16%
• Pregnancy 33%
• Premature Labor 16%
• Progesterone 33%
• Progesterone Receptor 100%
• Progesterone Receptor Modulator 66%
• Receptor 16%
• SCID Mouse 16%
• Selectivity 16%
• Steroid Receptor 16%
• Target Tissue 16%
• Therapeutic Procedure 33%
• Tissues 16%
• Ulipristal 66%
• Uterine Fibroid 50%
• Xenograft 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Androgen Receptor 16%
• Animal 50%
• Antigestagen 16%
• Antiglucocorticoid 16%
• Drug 16%
• Endometriosis 33%
• Estradiol Receptor 16%
• Estrogen 16%
• Glucocorticoid 16%
• Glucocorticoid Receptor 16%
• Gynecologic Disease 16%
• Human 16%
• Leporidae 16%
• Ligand 16%
• Mifepristone 33%
• Mineralocorticoid Receptor 16%
• Mouse Model 16%
• NOD SCID Mouse 16%
• Pharmacodynamics 16%
• Premature Labor 16%
• Progesterone 33%
• Progesterone Receptor 100%
• Progesterone Receptor Modulator 66%
• Progestin 33%
• Receptor 16%
• Synergism 16%
• Ulipristal 66%
• Uterus Myoma 50%